Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Core Insights - Alzamend Neuro, Inc. has initiated its first Phase II clinical study of AL001, targeting conditions such as Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder [1][4] - The study aims to evaluate AL001's ability to deliver lithium more effectively in the brain compared to existing lithium salts, with a focus on safety and reduced side effects [2][5] Company Overview - Alzamend Neuro is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for Alzheimer's, bipolar disorder, major depressive disorder, and post-traumatic stress disorder [6] - The company's pipeline includes two main candidates: AL001, a lithium-delivery system, and ALZN002, a cell-based therapeutic vaccine targeting Alzheimer's [6] Product Details - AL001 is designed to provide the benefits of lithium while minimizing toxicities associated with traditional lithium therapies, potentially eliminating the need for therapeutic drug monitoring [3][5] - Previous studies indicate that AL001 allows for better brain absorption of lithium while maintaining lower blood levels, which could lead to safer treatment options [2][5] Clinical Study Insights - The Phase II study will involve healthy human subjects to establish a baseline for AL001's effectiveness and safety profile [2][4] - Topline data from the study is expected by the end of the year, with plans for head-to-head comparisons against marketed lithium carbonate products [4][9]